

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM854513

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
RIBON THERAPEUTICS, INC.		11/17/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE		
<b>Street Address:</b>	140 SHERMAN STREET, FOURTH FLOOR		
<b>City:</b>	FAIRFIELD		
<b>State/Country:</b>	CONNECTICUT		
<b>Postal Code:</b>	06824		
<b>Entity Type:</b>	TRUST COMPANY: NEW HAMPSHIRE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	6931419	RIBON	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6505657100		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6505657022		
<b>Email:</b>	kceron@sidley.com		
<b>Correspondent Name:</b>	Karla Ceron		
<b>Address Line 1:</b>	1001 Page Mill Road, Building 1		
<b>Address Line 4:</b>	Palo Alto, CALIFORNIA 94304		
<b>ATTORNEY DOCKET NUMBER:</b>	100085.30140		
<b>NAME OF SUBMITTER:</b>	Karla Ceron		
<b>SIGNATURE:</b>	/karla ceron/		
<b>DATE SIGNED:</b>	11/17/2023		
<b>Total Attachments: 7</b>			
source=02 IPSA - Ribon Therapeutics (11.17.2023)#page1.tif			
source=02 IPSA - Ribon Therapeutics (11.17.2023)#page2.tif			
source=02 IPSA - Ribon Therapeutics (11.17.2023)#page3.tif			
source=02 IPSA - Ribon Therapeutics (11.17.2023)#page4.tif			
source=02 IPSA - Ribon Therapeutics (11.17.2023)#page5.tif			

CH \$40.00 6931419

source=02 IP SA - Ribon Therapeutics (11.17.2023)#page6.tif

source=02 IP SA - Ribon Therapeutics (11.17.2023)#page7.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “**Agreement**”) is entered into as of November 17, 2023, between **RIBON THERAPEUTICS, INC.**, a Delaware corporation (“**Grantor**”) and **ANKURA TRUST COMPANY, LLC**, as collateral trustee for Lenders (in such capacity, “**Collateral Trustee**”).

### RECITALS

A. Grantor, K2 HealthVentures LLC, as administrative agent, the lender from time to time party thereto (collectively “**Lenders**”), and Collateral Trustee, as collateral trustee for Lenders, has entered into a Loan and Security Agreement dated as of April 12, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the “**Loan Agreement**”). Defined terms used herein without definition shall have the meanings set forth in the Loan Agreement.

B. The Obligations are secured by the Collateral, as defined in the Loan Agreement, including without limitation, all of Grantor’s Intellectual Property.

### AGREEMENT

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, Grantor and Collateral Trustee hereby agree:

1. To secure the Obligations, Grantor grants Collateral Trustee a security interest in all of Grantor’s right, title and interest in its Intellectual Property constituting Collateral. Grantor hereby confirms that the attached schedules of Grantor’s copyright, patent and trademark applications and registrations, which are registered or filed with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, attached hereto as Exhibits A, B and C hereto, respectively, are complete and accurate as of the date hereof.

2. Grantor hereby authorizes Collateral Trustee to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate of this Agreement containing amended exhibits reflecting such new Intellectual Property with the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

3. This Agreement shall be exclusively (without regard to any rules or principles relating to conflicts of laws) governed by, enforced and construed in accordance with the laws of the state of New York and the federal laws of the United States applicable therein.

4. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. The words “execution,” “signed,” “signature” and words of like import shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act. Delivery of an executed counterpart of a signature page to this Agreement by electronic means including by email delivery of a “.pdf” format data file shall be effective as delivery of an original executed counterpart of this Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

IN WITNESS WHEREOF, the undersigned have duly executed this Intellectual Property Security Agreement as of the first date written above.

Address of Grantor:

35 Cambridgepark Drive, Suite 300  
Cambridge, MA 02140  
Attention: Prakash Raman, CEO

GRANTOR:

RIBON THERAPEUTICS, INC.

By Prakash Raman  
Name: Prakash Raman  
Title: Chief Executive Officer

Address of Collateral Trustee:

140 Sherman Street, Fourth Floor  
Fairfield, CT 06824  
Attention: Beth Micena

COLLATERAL TRUSTEE:

ANKURA TRUST COMPANY, LLC

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

IN WITNESS WHEREOF, the undersigned have duly executed this Intellectual Property Security Agreement as of the first date written above.

Address of Grantor:

35 Cambridgepark Drive, Suite 300  
Cambridge, MA 02140  
Attention: Paul Brannelly, CFO

GRANTOR:

RIBON THERAPEUTICS, INC.

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Address of Collateral Trustee:

140 Sherman Street, Fourth Floor  
Fairfield, CT 06824  
Attention: Beth Micena

COLLATERAL TRUSTEE:

ANKURA TRUST COMPANY, LLC

By: Beth Micena

Name: Beth Micena

Title: Managing Director

EXHIBIT A  
COPYRIGHTS

<u>OWNER</u>	<u>DESCRIPTION</u>	<u>REGISTRATION NUMBER</u>	<u>REGISTRATION DATE</u>
None.			

## EXHIBIT B

## PATENTS

OWNER	DESCRIPTION	PATENT / APPLICATION NUMBER	ISSUE / APPLICATION DATE
RIBON THERAPEUTICS, INC.	QUINAZOLINONES AS PARP14 INHIBITORS (0005001)	10562891	2/18/2020
RIBON THERAPEUTICS, INC.	QUINAZOLINONES AS PARP14 INHIBITORS (0005002)	11008308	5/18/2021
RIBON THERAPEUTICS, INC.	QUINAZOLINONES AS PARP14 INHIBITORS (0005003)	17/230099	4/14/2021
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0006001)	10550105	2/4/2020
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0006002)	10870641	12/22/2020
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0006003)	11014913	5/25/2021
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0006004)	11566020	1/31/2023
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0006005)	17/974830	10/27/2022
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0013001)	11691969	7/4/2023
RIBON THERAPEUTICS, INC.	PYRIDAZINONES AS PARP7 INHIBITORS (0013002)	18/196601	5/12/2023
RIBON THERAPEUTICS, INC.	SCREENING METHODS FOR PARP MODULATORS (0007001)	11293927	4/5/2022
RIBON THERAPEUTICS, INC.	SCREENING METHODS FOR PARP MODULATORS (0007002)	17/697322	3/17/2022
RIBON THERAPEUTICS, INC.	SOLID FORMS OF A PARP14 INHIBITOR (0020001)	18/107164	2/8/2023
RIBON THERAPEUTICS, INC.	SOLID FORMS OF A PARP7 INHIBITOR (0011US1)	17/607090	4/28/2020
RIBON THERAPEUTICS, INC.	TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY (0010US1)	17/619459	6/18/2020
RIBON THERAPEUTICS, INC.	METHODS OF TREATING INFLAMMATORY DISEASES (0019001)	17/586962	1/28/2022
RIBON THERAPEUTICS, INC.	DOSAGE REGIMENS FOR PARP7 INHIBITORS (0017002)	18/371626	9/22/2023
RIBON THERAPEUTICS, INC.	TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY (0022001)	18/227639	7/28/2023

RIBON THERAPEUTICS, INC.	TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY (0023001)	18/227643	7/28/2023
RIBON THERAPEUTICS, INC.	DOSAGE REGIMENS FOR PARP14 INHIBITORS (0025P01)	63/535775	8/31/2023



EXHIBIT C

TRADEMARKS

<u>OWNER</u>	<u>DESCRIPTION</u>	<u>REGISTRATION/ SERIAL NUMBER</u>	<u>REGISTRATION/ APPLICATION DATE</u>
RIBON THERAPEUTICS, INC.	RIBON	6931419	12/20/2022